Clinical Trials Browser

Active not recruiting × Dasatinib × 90 days × Clear all

NCT00792948 2026-04-13

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Phase 2 Active not recruiting

97 enrolled 7 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01660971 2026-04-13

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02143414 2026-04-13

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Phase 2 Active not recruiting

53 enrolled 12 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04329325 2026-04-07

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3 Active not recruiting

405 enrolled 18 charts 3 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03516279 2026-04-03

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT06645886 2026-03-25

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

Phase 1 Active not recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT00070499 2026-03-23

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Phase 2 Active not recruiting

406 enrolled 11 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02389309 2026-03-09

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

Phase 1 Active not recruiting

Brain Neoplasms

NCT02689440 2026-03-05

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03020030 2026-01-22

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04733534 2026-01-20

An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer

Phase 2 Active not recruiting

Frailty, Neoplasms